Status: Recruiting
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
This is a Phase II study to determine the rate of stabilization or disease improvement from investigational decitabine/cedazuridine (INQOVI) treatment in subjects with BRCA1-Associated Protein-1 (BAP1) Cancer Predisposition Syndrome (CPDS) and subclinical, early-stage mesothelioma. Progression-free survival (PFS) will also be determined for treated subjects, and the treatment safety (toxicity) evaluated....
Participants needed: 15
Trial details
Phase: Phase 2Age: 18-120Biological sex: AllType: InterventionalSponsor: National Cancer Institute (NCI)Updated: Sep 23, 2026Locations: 1
Eligibility criteria
Participants with history of germline BRCA1-Associated Protein-1 (BAP1) mutation... [+22]
Participants with cancers requiring frontline standard of care treatment. [+11]